The Johns Hopkins Center for Health Security is excited to announce that we will be presenting a tailored version of the original day-long Clade X exercise at the NACCHO-hosted Preparedness Summit in Saint Louis, MO on Tuesday, March 26 from 1:30-5:00PM. The exercise, “Clade X: State and Local,” will focus on domestic public health challenges during a severe pandemic and illustrate high-level strategic decisions and policies that the US will need to pursue in order to diminish its consequences. The exercise debrief will be conducted by Dr. Stephen Redd, Director for the Center for Preparedness and Response at the US CDC. Participants are encouraged to pre-register by using these instructions, also available at the Preparedness Summit online schedule. If you plan on attending the Preparedness Summit, we hope to see you at Clade X: State and Local!
WHO Global Influenza Strategy 2019-2030 (Avian Flu Diary) We are just over a month shy of the 10th anniversary of the HHS Declaration of a Public Health Emergency due to the emergence of a new swine-origin H1N1 flu virus, which by early summer of 2009 would be declared a pandemic.
Go to article
How Africa Can Quell the Next Disease Outbreaks(Nature) This week, African and global health experts and policymakers are gathering in Addis Ababa to discuss how to enable national public-health institutions (NPHIs) to keep emerging and re-emerging infectious disease in check. At the top of the agenda must be empowering local leadership to act fast.
Go to report
Medicine & Public Health
TB Medicine Pretomanid Enters Regulatory Review Process in the United States (TB Alliance) TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the treatment of extensively drug-resistant (XDR) TB, treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.
Go to report